Protective Role of Endogenous Gangliosides for Lysosomal Pathology in a Cellular Model of Synucleinopathies

Abstract

Gangliosides may be involved in the pathogenesis of Parkinson's disease and related disorders, although the precise mechanisms governing this involvement remain unknown. In this study, we determined whether changes in endogenous ganglioside levels affect lysosomal pathology in a cellular model of synucleinopathy. For this purpose, dementia with Lewy body-linked P123H ␤-synuclein (␤-syn) neuroblastoma cells transfected with ␣-synuclein were used as a model system because these cells were characterized as having extensive formation of lysosomal inclusions bodies. Treatment of these cells with D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), an inhibitor of glycosyl ceramide synthase, resulted in various features of lysosomal pathology, including compromised lysosomal activity, enhanced lysosomal membrane permeabilization, and increased cytotoxicity. Consistent with these findings, expression levels of lysosomal membrane proteins, ATP13A2 and LAMP-2, were significantly decreased, and electron microscopy demonstrated alterations in the lysosomal membrane structures. Furthermore, the accumulation of both P123H ␤-syn and ␣-synuclein proteins was significant in PDMP-treated cells because of the suppressive effect of PDMP on the autophagy pathway. Finally, the detrimental effects of PDMP on lysosomal pathology were significantly ameliorated by the addition of gangliosides to the cultured cells. These data suggest that endogenous gangliosides may play protective roles against the lysosomal pathology of synucleinopathies. (Am J

Heat Shock Protein 70.1 (Hsp70.1) Affects Neuronal Cell Fate by Regulating Lysosomal Acid Sphingomyelinase

“…Isolation of Lysosomal and Cytosolic Fractions from the Motor Cortex and CA1-The cytosolic and enriched lysosomal fractions were prepared using a lysosome enrichment kit for tissue and cultured cells (Thermo Scientific) with some modifications as described in detail (20).…”

Glucocerebrosidase, a new player changing the old rules in Lewy body diseases

“…Therefore, these results suggest a positive feedback loop between α -synuclein accumulation and GCase abnormalities. In contrast, another series of in vitro studies showed that binding of gangliosides inhibits the aggregation of α -synuclein (Martinez et al , 2007 ;Wei et al , 2009 ). Therefore, the effects of the direct binding of glycosphingolipids on α -synuclein aggregation remain controversial.…”

Dysfunction of two lysosome degradation pathways of α-synuclein in Parkinson’s disease: potential therapeutic targets?

“…, an inhibitor of glycosyl ceramide synthase, results in various pathological features, including compromised lysosomal activity, enhanced lysosomal membrane permeabilization, and increased cytotoxicity [39] .…”

“…Natural and semisynthetic gangliosides are considered to be possible therapeutic agents for neurodegenerative disorders [38] . In a study by Wei et al [39] , cells overexpressing P123H β-syn were transfected with control vectors, Wt α-syn, or A53T α-syn. Treatment of these cells…”